On April 14, 2025, Peijia Medical announced that the NMPA has formally accepted the registration application for the TaurusTrio™ Transcatheter Aortic Valve (TAV) System. 

TaurusTrio™ TAV system is developed and manufactured by the Company based on the exclusive license obtained from JenaValve Technology, Inc., which is designed for treating patients with native symptomatic severe AR through transfemoral access. The System was accepted by the Special Review and Approval Procedure for Innovative Medical Devices of the NMPA in June 2023 and will enjoy priority in the appraisal and approval procedures during the registration application process.